In order to further follow through the spirit of General Secretary Xi Jinping's important speech during his visit to Shanghai, implement the requirements of the "Three-year Plan of Action for Promoting the High Quality Development of the Biopharmaceutical Industry in Shanghai", and speed up the expansion of the "innovative medicine" industry, on the morning of April 2nd, the Conference on Promoting High Quality Development of Biomedical Industry was held at Pudong. Weng Zuliang, Member of Standing Committee of Shanghai Municipal CPC Committee and Secretary of Pudong New Area, was present and unveiled Zhangjiang Innovative Pharmaceutical Industry Base.Wu Qing, Vice Mayor of Shanghai, made a speech. Chen Mingbo, Deputy Secretary-General of Municipal Government, and Hang Yingwei, Director of Pudong New Area, unveiled Zhangjiang Medical Device Industry Base. Relevant leaders were also present, including Wu Jincheng, Chairman of Shanghai Municipal Commission of Economy and Informatization, Zhang Quan, Director of Municipal Science and Technology Commission, Peng Song, Executive Deputy Director of Construction Office of Municipal Science and Technology Innovation Center, and Guan Xiaojun, Deputy Director of Pudong New Area.
At the conference, Zhangjiang Science City Construction Management Office signed the liability statement for base construction with Zhangjiang Group. A number of key projects and platform projects were also signed at the meeting.The 30 contracted projects are Zhangjiang Innovative Pharmaceutical Industry Base Project, Zhangjiang Medical Device Industry Base Project, Headquarters Enterprise and Diseno Old Port Base Project, with a total investment of nearly 35 billion yuan and an estimated production capacity of 80 billion yuan. These projects aim to solve the industrial space of 100 innovative pharmaceutical products and strive to achieve the approval of 15 Class I new drugs and the approval of more than 50 Class III medical devices.
Mr. Wu demanded in his speech that there are three important points for development of biomedical industry at Pudong New Area. First, it is important to combine with high-quality development, improve economic density and input-output efficiency, improve the ability to allocate global resources, aim at the frontier of science and technology as well as key areas, and make major breakthroughs as soon as possible, making biomedicine a powerful momentum for high-quality development; Second, it is wise to combine with the "Four Brands" of Shanghai, further cultivate the innovative ecology of the biomedical industry, promote the implementation of the achievements, lay out major manufacturing projects and major innovative projects, and build a number of benchmarking enterprises at home and abroad for the "Made in Shanghai" brand of biomedical industry; Third, it is advisable to combine with a first-class business environment, give full play to the pilot role of Shanghai Free Trade Zone, further promote pilot reforms like drug listing licensing holder system, explore pilot reforms in other areas, promote efficiency change and power change, form institutional advantages and pioneering advantages, and enhance the attractiveness, creativity and competitiveness of the biomedical industry.
After more than 20 years of development, the biomedical industry at Pudong New Area has formed a complete industrial chain, value chain and innovation chain, gathering various industrial elements. In 2018, the scale of biomedical industry at Pudong New Area reached 67.2 billion yuan, of which the output value of manufacturing industry above the scale was 54.8 billion yuan, an increase of 16.2% year on year, 6 percentage points higher than that of Shanghai, accounting for nearly half of the city's industrial output value. In 2018, four innovative drugs were approved for market in Shanghai, all of which came from Pudong New Area, 2 of which were Class I new drugs and 20 of which were Class III new medical devices. At the same time, there are more than 100 innovative drugs in Phase II and III clinical trials at Pudong New Area, of which more than 30 are Class I new drugs and 20-30 Class III medical devices are approved to market every year. In order to promote the transformation of innovative pharmaceutical products, according to the plan, Pudong plans to build a new industrial base of nearly 10 square kilometers with Zhangjiang Innovative Pharmaceutical Industry Base and Zhangjiang Medical Device Industry Base. By 2020, the total industrial output value of manufacturing industry and the revenue of high-tech service industry will reach 100 billion yuan; By 2025, an international biomedical innovation and industrial cluster will be basically established, and Pudong biomedical industry will be promoted to the top of the global value chain.
